These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 31511492)

  • 1. Myelofibrosis in 2019: moving beyond JAK2 inhibition.
    Schieber M; Crispino JD; Stein B
    Blood Cancer J; 2019 Sep; 9(9):74. PubMed ID: 31511492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
    Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
    PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.
    Tefferi A; Pardanani A; Gangat N
    Haematologica; 2023 Nov; 108(11):2919-2932. PubMed ID: 36861402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.
    Randhawa J; Ostojic A; Vrhovac R; Atallah E; Verstovsek S
    J Hematol Oncol; 2012 Aug; 5():43. PubMed ID: 22852872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.
    Chen YY; Huang CE; Lee KD; Chen CC
    Hematology; 2016 Jan; 21(1):3-9. PubMed ID: 26214121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for combination therapy in myelofibrosis.
    Mascarenhas J
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):197-208. PubMed ID: 25189730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How many JAK inhibitors in myelofibrosis?
    Ferreira BV; Harrison C
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):187-95. PubMed ID: 25189729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel myelofibrosis treatment strategies: potential partners for combination therapies.
    Stein BL; Swords R; Hochhaus A; Giles F
    Leukemia; 2014 Nov; 28(11):2139-47. PubMed ID: 24888274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.
    Kirabo A; Park SO; Wamsley HL; Gali M; Baskin R; Reinhard MK; Zhao ZJ; Bisht KS; Keserű GM; Cogle CR; Sayeski PP
    Am J Pathol; 2012 Sep; 181(3):858-65. PubMed ID: 22796437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications.
    Ross DM; Babon JJ; Tvorogov D; Thomas D
    Haematologica; 2021 May; 106(5):1244-1253. PubMed ID: 33472356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
    Hobbs GS; Rozelle S; Mullally A
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the diagnosis and management of primary myelofibrosis.
    Takenaka K; Shimoda K; Akashi K
    Korean J Intern Med; 2018 Jul; 33(4):679-690. PubMed ID: 29665657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.
    Vaddi K; Sarlis NJ; Gupta V
    Expert Opin Pharmacother; 2012 Nov; 13(16):2397-407. PubMed ID: 23051187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in JAK2 inhibition for the treatment of myelofibrosis.
    Rippel N; Kremyanskaya M
    Expert Opin Pharmacother; 2024 Jun; 25(9):1175-1186. PubMed ID: 38919983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of myelofibrosis: JAK inhibition and beyond.
    Stahl M; Zeidan AM
    Expert Rev Hematol; 2017 May; 10(5):459-477. PubMed ID: 28395559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond JAK inhibitor therapy in myelofibrosis.
    Odenike O
    Hematology Am Soc Hematol Educ Program; 2013; 2013():545-52. PubMed ID: 24319230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels.
    Lewandowski K; Kanduła Z; Gniot M; Paczkowska E; Nawrocka PM; Wojtaszewska M; Janowski M; Mariak M; Handschuh L; Kozlowski P
    Ann Hematol; 2022 Dec; 101(12):2665-2677. PubMed ID: 36266510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes.
    Aguirre LE; Jain A; Ball S; Ali NA; Volpe VO; Tinsley-Vance S; Sallman D; Sweet K; Lancet J; Padron E; Yun S; Kuykendall A; Komrokji R
    Clin Lymphoma Myeloma Leuk; 2024 Jul; 24(7):459-467. PubMed ID: 38548563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?
    Lancman G; Mascarenhas J
    Expert Rev Hematol; 2017 Jan; 10(1):23-28. PubMed ID: 27882812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.